Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
Rhea-AI Summary
AnaptysBio (ANAB) has announced it will host an investor call and live webcast on February 12, 2025, at 8:30 AM ET to present top-line data from its global Phase 2b RENOIR clinical trial. The trial evaluates rosnilimab, a PD-1+ T cells depleter and agonist, for the treatment of moderate-to-severe rheumatoid arthritis. The data will be released through a morning press release and discussed during the webcast, which will be accessible via the company's investor relations website. A replay will remain available for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – ANAB
On the day this news was published, ANAB gained 30.51%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
A live webcast of the call will be available on the Anaptys website at: https://ir.anaptysbio.com/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When will AnaptysBio (ANAB) release Phase 2b RENOIR trial results for rosnilimab?
What is the purpose of AnaptysBio's RENOIR trial for rosnilimab?
How can investors access ANAB's rosnilimab Phase 2b data presentation?
How long will the replay of ANAB's rosnilimab Phase 2b data presentation be available?
